U
ECYT

UBS’s Endocyte, Inc. Common Stock ECYT Stock Holding History

UBS’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$147K Buy
24,100
+13,200
+121% +$90.2K ﹤0.01% 5519
2014
Q2 		$72K Sell
10,900
-6,400
-37% -$72.1K ﹤0.01% 6377
2014
Q1 		$412K Buy
17,300
+6,300
+57% +$91.3K ﹤0.01% 4447
2013
Q4 		$117K Buy
+11,000
New +$121K ﹤0.01% 5892

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS's ECYT Position: Q3 2014 in Review

UBS held its Endocyte, Inc. Common Stock (ECYT) position steady in Q3 2014 at 6,000 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #7244.

UBS first reported a position in ECYT in Q2 2013 and has held it in 6 quarters since. The position peaked at $324K in Q2 2013. 101 funds tracked by Wall St. Rank hold ECYT as of Q3 2014.

  • UBS held 6,000 shares of Endocyte, Inc. Common Stock worth $36K as of Q3 2014.
  • UBS left its Endocyte, Inc. Common Stock share count unchanged in Q3 2014.
  • Endocyte, Inc. Common Stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7244 holding.
  • UBS first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and has held it in 6 quarters since.
  • UBS's Endocyte, Inc. Common Stock position peaked at $324K in Q2 2013.
  • 101 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.